Anti-LFA-1 Monotherapy Prevents Neointimal Formation in a Murine Model of Transplant Intimal Hyperplasia

Behzad Soleimani, Grazyna Wieczorek, Andreas Katopodis, Gerhard Zenke, Andrew J T George, Philip I. Hornick, Gabriele Weitz-Schmidt

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Cardiac allograft vasculopathy (CAV) is the pre-eminent cause of late cardiac allograft failure. It is characterized by a concentric intimal hyperplasia, which we designate transplant intimal hyperplasia (TIH). To date, blockade of the adhesion molecule lymphocyte function-associated antigen-1 (LFA-1) has been shown to be effective in preventing TIH in experimental models of transplantation, but only when combined with other immunosuppressants. In this study we explored the impact of monotherapy against LFA-1 in a carotid artery allograft model of TIH. Methods: B10A(2R) (H-2h2) mice were used as donors and C57BL/6 (H-2b) mice used as recipients. The recipients were treated with a monoclonal antibody against LFA-1α (M17/4) or isotype-matched control immunoglobulin. Grafts were harvested after 35 days and analyzed by histomorphometry and immunohistochemistry. Blood samples were taken and analyzed by differential cell count and alloantibody levels. Results: We found that treatment with M17/4 resulted in a significant reduction in TIH compared with controls. Immunostaining revealed that LFA-1α blockade inhibited CD45+ leukocyte infiltration, prevented intimal smooth muscle cell (SMC) proliferation, and preserved the medial SMC population. Finally, we demonstrated a reduction in the serum alloantibody titer in the group treated with anti-LFA-1α when compared with controls. Conclusions: We have demonstrated for the first time that LFA-1α blockade on its own can prevent development of TIH in an experimental model. The concept of modulating LFA-1α-mediated leukocyte migration and T-cell activation may therefore be of relevance to clinical cardiac transplantation and, as such, represents a potential target for therapeutic intervention against clinical CAV.

Original languageEnglish (US)
Pages (from-to)724-731
Number of pages8
JournalJournal of Heart and Lung Transplantation
Volume26
Issue number7
DOIs
StatePublished - Jul 1 2007

Fingerprint

Tunica Intima
Lymphocyte Function-Associated Antigen-1
Hyperplasia
Transplants
Allografts
Isoantibodies
Smooth Muscle Myocytes
Leukocytes
Theoretical Models
Heart Transplantation
Immunosuppressive Agents
Carotid Arteries
Immunoglobulins
Heart Failure
Cell Count
Transplantation
Immunohistochemistry
Monoclonal Antibodies
Cell Proliferation
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Soleimani, Behzad ; Wieczorek, Grazyna ; Katopodis, Andreas ; Zenke, Gerhard ; George, Andrew J T ; Hornick, Philip I. ; Weitz-Schmidt, Gabriele. / Anti-LFA-1 Monotherapy Prevents Neointimal Formation in a Murine Model of Transplant Intimal Hyperplasia. In: Journal of Heart and Lung Transplantation. 2007 ; Vol. 26, No. 7. pp. 724-731.
@article{720798839352480eb7c2a1d51e00bd1b,
title = "Anti-LFA-1 Monotherapy Prevents Neointimal Formation in a Murine Model of Transplant Intimal Hyperplasia",
abstract = "Background: Cardiac allograft vasculopathy (CAV) is the pre-eminent cause of late cardiac allograft failure. It is characterized by a concentric intimal hyperplasia, which we designate transplant intimal hyperplasia (TIH). To date, blockade of the adhesion molecule lymphocyte function-associated antigen-1 (LFA-1) has been shown to be effective in preventing TIH in experimental models of transplantation, but only when combined with other immunosuppressants. In this study we explored the impact of monotherapy against LFA-1 in a carotid artery allograft model of TIH. Methods: B10A(2R) (H-2h2) mice were used as donors and C57BL/6 (H-2b) mice used as recipients. The recipients were treated with a monoclonal antibody against LFA-1α (M17/4) or isotype-matched control immunoglobulin. Grafts were harvested after 35 days and analyzed by histomorphometry and immunohistochemistry. Blood samples were taken and analyzed by differential cell count and alloantibody levels. Results: We found that treatment with M17/4 resulted in a significant reduction in TIH compared with controls. Immunostaining revealed that LFA-1α blockade inhibited CD45+ leukocyte infiltration, prevented intimal smooth muscle cell (SMC) proliferation, and preserved the medial SMC population. Finally, we demonstrated a reduction in the serum alloantibody titer in the group treated with anti-LFA-1α when compared with controls. Conclusions: We have demonstrated for the first time that LFA-1α blockade on its own can prevent development of TIH in an experimental model. The concept of modulating LFA-1α-mediated leukocyte migration and T-cell activation may therefore be of relevance to clinical cardiac transplantation and, as such, represents a potential target for therapeutic intervention against clinical CAV.",
author = "Behzad Soleimani and Grazyna Wieczorek and Andreas Katopodis and Gerhard Zenke and George, {Andrew J T} and Hornick, {Philip I.} and Gabriele Weitz-Schmidt",
year = "2007",
month = "7",
day = "1",
doi = "10.1016/j.healun.2007.04.007",
language = "English (US)",
volume = "26",
pages = "724--731",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "7",

}

Anti-LFA-1 Monotherapy Prevents Neointimal Formation in a Murine Model of Transplant Intimal Hyperplasia. / Soleimani, Behzad; Wieczorek, Grazyna; Katopodis, Andreas; Zenke, Gerhard; George, Andrew J T; Hornick, Philip I.; Weitz-Schmidt, Gabriele.

In: Journal of Heart and Lung Transplantation, Vol. 26, No. 7, 01.07.2007, p. 724-731.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-LFA-1 Monotherapy Prevents Neointimal Formation in a Murine Model of Transplant Intimal Hyperplasia

AU - Soleimani, Behzad

AU - Wieczorek, Grazyna

AU - Katopodis, Andreas

AU - Zenke, Gerhard

AU - George, Andrew J T

AU - Hornick, Philip I.

AU - Weitz-Schmidt, Gabriele

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Background: Cardiac allograft vasculopathy (CAV) is the pre-eminent cause of late cardiac allograft failure. It is characterized by a concentric intimal hyperplasia, which we designate transplant intimal hyperplasia (TIH). To date, blockade of the adhesion molecule lymphocyte function-associated antigen-1 (LFA-1) has been shown to be effective in preventing TIH in experimental models of transplantation, but only when combined with other immunosuppressants. In this study we explored the impact of monotherapy against LFA-1 in a carotid artery allograft model of TIH. Methods: B10A(2R) (H-2h2) mice were used as donors and C57BL/6 (H-2b) mice used as recipients. The recipients were treated with a monoclonal antibody against LFA-1α (M17/4) or isotype-matched control immunoglobulin. Grafts were harvested after 35 days and analyzed by histomorphometry and immunohistochemistry. Blood samples were taken and analyzed by differential cell count and alloantibody levels. Results: We found that treatment with M17/4 resulted in a significant reduction in TIH compared with controls. Immunostaining revealed that LFA-1α blockade inhibited CD45+ leukocyte infiltration, prevented intimal smooth muscle cell (SMC) proliferation, and preserved the medial SMC population. Finally, we demonstrated a reduction in the serum alloantibody titer in the group treated with anti-LFA-1α when compared with controls. Conclusions: We have demonstrated for the first time that LFA-1α blockade on its own can prevent development of TIH in an experimental model. The concept of modulating LFA-1α-mediated leukocyte migration and T-cell activation may therefore be of relevance to clinical cardiac transplantation and, as such, represents a potential target for therapeutic intervention against clinical CAV.

AB - Background: Cardiac allograft vasculopathy (CAV) is the pre-eminent cause of late cardiac allograft failure. It is characterized by a concentric intimal hyperplasia, which we designate transplant intimal hyperplasia (TIH). To date, blockade of the adhesion molecule lymphocyte function-associated antigen-1 (LFA-1) has been shown to be effective in preventing TIH in experimental models of transplantation, but only when combined with other immunosuppressants. In this study we explored the impact of monotherapy against LFA-1 in a carotid artery allograft model of TIH. Methods: B10A(2R) (H-2h2) mice were used as donors and C57BL/6 (H-2b) mice used as recipients. The recipients were treated with a monoclonal antibody against LFA-1α (M17/4) or isotype-matched control immunoglobulin. Grafts were harvested after 35 days and analyzed by histomorphometry and immunohistochemistry. Blood samples were taken and analyzed by differential cell count and alloantibody levels. Results: We found that treatment with M17/4 resulted in a significant reduction in TIH compared with controls. Immunostaining revealed that LFA-1α blockade inhibited CD45+ leukocyte infiltration, prevented intimal smooth muscle cell (SMC) proliferation, and preserved the medial SMC population. Finally, we demonstrated a reduction in the serum alloantibody titer in the group treated with anti-LFA-1α when compared with controls. Conclusions: We have demonstrated for the first time that LFA-1α blockade on its own can prevent development of TIH in an experimental model. The concept of modulating LFA-1α-mediated leukocyte migration and T-cell activation may therefore be of relevance to clinical cardiac transplantation and, as such, represents a potential target for therapeutic intervention against clinical CAV.

UR - http://www.scopus.com/inward/record.url?scp=34347248008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347248008&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2007.04.007

DO - 10.1016/j.healun.2007.04.007

M3 - Article

C2 - 17613404

AN - SCOPUS:34347248008

VL - 26

SP - 724

EP - 731

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 7

ER -